Ecallantide: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "rxn" to "reaction") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Acute hereditary angioedema]]=== | |||
*30mg SQ | *30mg SQ | ||
*Max 60mg/ 24 hr | *Max 60mg/ 24 hr | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Acute hereditary angioedema]] (>12yo)=== | |||
*30mg SQ | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | ||
Latest revision as of 16:07, 17 August 2019
General
- Type: Kallikrein inhibitor for angioedema
- Dosage Forms: 30mg
- Routes of Administration: SQ
- Common Trade Names: Kalbitor
Adult Dosing
Acute hereditary angioedema
- 30mg SQ
- Max 60mg/ 24 hr
Pediatric Dosing
Acute hereditary angioedema (>12yo)
- 30mg SQ
Special Populations
- Pregnancy Rating:C
- Lactation risk:Safety Unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- hypersensitivity reaction
Common
- headache
- nausea
- fatigue
- diarrhea
- URI
- injection site reaction
- nasopharyngitis
- vomiting
- pruritus
- abdominal pain
- fever
- anaphylaxis
Pharmacology
- Half-life: 2h
- Metabolism: CYP450
- Excretion: Urine
- Mechanism of Action: selectively, reversibly inhibits plasma kallikrein, preventing bradykinin generation
Comments
- Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema